SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2085)4/21/2004 12:22:24 AM
From: Ian@SI  Respond to of 3044
 
In Lenz's section of the CME, he states, "Importantly, in this Phase I trial, we saw a major clinical response in a patient with lung cancer, indicating and proving that as a single agent, this drug has efficacy in solid tumors. "

Obviously, the statement is a "little" strong for a Ph1 trial, but it's encouraging to see such a forceful statement.



To: tuck who wrote (2085)4/21/2004 8:44:28 AM
From: tom pope  Read Replies (1) | Respond to of 3044
 
Just be thankful I don't post abstracts that are as cryptic as some of Rick's or Miljenko's. Those guys often make you work to connect the dots. Which is actually a good exercise.

Truer words were never spoken.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News